0R19 Stock Chart & Stats
$164.78
$3.01(1.82%)
At close: 4:00 PM EDT
$164.78
$3.01(1.82%)
Day’s Range― - ―
52-Week Range$139.58 - $212.51
Previous CloseN/A
Volume117.00
Average Volume (3M)1.01K
Market Cap
$45.64B
Enterprise Value$60.39K
Total Cash (Recent Filing)$709.00M
Total Debt (Recent Filing)$14.52B
Price to Earnings (P/E)41.9
Beta0.69
Next Earnings
Nov 05, 2026EPS Estimate
4.08Next Dividend Ex-DateN/A
Dividend Yield29.99%
Share Statistics
EPS (TTM)3.32
Shares Outstanding275,540,440
10 Day Avg. Volume1,353
30 Day Avg. Volume1,010
Financial Highlights & Ratios
PEG Ratio-37.04
Price to Book (P/B)1.66
Price to Sales (P/S)1.93
P/FCF Ratio15.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$184.50Price Target Upside11.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)12.61
Revenue Forecast (FY)$19.22B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Installed BaseBD's core revenue mix — high-volume single-use consumables plus installed capital equipment — creates durable, repeatable demand. Installed platforms drive consumable pull‑through and create predictable revenue streams, supporting steady topline and cash conversion over multiple quarters.
Diversified Growth PlatformsBroad-based growth across many franchises reduces dependence on any single product or region. Multiple double-digit growth platforms (e.g., biologic delivery, monitoring, tissue regen) provide structural upside and buffer cyclical weakness in specific end markets over a multi‑quarter horizon.
Productivity Driving Margins & ServiceOperational reforms (BD Excellence) materially lowered costs and improved service metrics. Sustainable productivity gains support margin resilience against input-cost and tariff pressures, while higher service levels reduce stockouts and protect recurring consumable revenue over the medium term.
Bears Say
Recent Revenue And Margin SoftnessA trailing‑twelve‑month revenue decline and compressed net margin reflect demand, mix, and cost pressure that can persist through multiple quarters. Lower FCF momentum constrains reinvestment and shareholder returns and raises the bar for margin recovery despite operational fixes.
Leverage Above Stated TargetLeverage near 2.9x limits financial flexibility for M&A, buybacks or capex until reduced. Servicing and refinancing risk becomes more relevant if margins remain pressured, and management must prioritize deleveraging which could compete with growth investments over the next several quarters.
Regulatory / Manufacturing OverhangAn ongoing FDA warning and prior ship hold signal elevated compliance risk at a manufacturing site. Remediation can be time‑consuming and costly, potentially disrupting supply of antiseptics or related products and creating long‑running operational and reputation headwinds.
0R19 FAQ
What was Becton Dickinson And Company’s price range in the past 12 months?
Becton Dickinson And Company lowest share price was $139.58 and its highest was $212.51 in the past 12 months.
What is Becton Dickinson And Company’s market cap?
Becton Dickinson And Company’s market cap is $45.64B.
When is Becton Dickinson And Company’s upcoming earnings report date?
Becton Dickinson And Company’s upcoming earnings report date is Nov 05, 2026 which is in 90 days.
How were Becton Dickinson And Company’s earnings last quarter?
Becton Dickinson And Company released its earnings results on Aug 06, 2026. The company reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.141 by $0.089.
Is Becton Dickinson And Company overvalued?
According to Wall Street analysts Becton Dickinson And Company’s price is currently Undervalued.
Does Becton Dickinson And Company pay dividends?
Becton Dickinson And Company pays a Quarterly dividend of $1.05 which represents an annual dividend yield of 29.99%. See more information on Becton Dickinson And Company dividends here
What is Becton Dickinson And Company’s EPS estimate?
Becton Dickinson And Company’s EPS estimate is 4.08.
How many shares outstanding does Becton Dickinson And Company have?
Becton Dickinson And Company has 275,540,440 shares outstanding.
What happened to Becton Dickinson And Company’s price movement after its last earnings report?
Becton Dickinson And Company reported an EPS of $3.23 in its last earnings report, beating expectations of $3.141. Following the earnings report the stock price went up 5.816%.
Which hedge fund is a major shareholder of Becton Dickinson And Company?
Currently, no hedge funds are holding shares in GB:0R19
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Becton Dickinson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$184.50 (11.97% Upside)
$184.50 (11.97% Upside)
Blogger Sentiment
Bullish
GB:0R19 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $404.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.80%
12-Months-Change
Fundamentals
Return on Equity
29.99%
Trailing 12-Months
Asset Growth
-6.67%
Trailing 12-Months
Company Description
Becton Dickinson And Company
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
0R19 Company Deck
0R19 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong execution across BD's focused med‑tech portfolio: revenue and adjusted EPS beat expectations, growth platforms showed double-digit expansion, productivity and cash flow improved materially, and the company raised EPS guidance. Headwinds are defined and manageable — chiefly Alaris remediation, tariffs, vaccine weakness in China and some margin pressure versus the prior year — and management laid out clear mitigation actions (pricing, productivity, commercial investments, AI for supply chain). Overall the positives materially outweigh the negatives.View all GB:0R19 earnings summaries0R19 Revenue Breakdown
52.45% Medical
23.66% Life Sciences
23.89% Interventional

0R19 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$184.50
▲(11.97% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Baxter International
―
―
Intuitive Surgical
―
Resmed
―
West Pharmaceutical Services
―







